These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30067547)

  • 1. Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
    Nicholas MN; Khoja L; Atenafu EG; Hogg D; Quirt I; Butler M; Joshua AM
    Melanoma Res; 2018 Dec; 28(6):571-577. PubMed ID: 30067547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.
    Khoja L; Atenafu EG; Suciu S; Leyvraz S; Sato T; Marshall E; Keilholz U; Zimmer L; Patel SP; Piperno-Neumann S; Piulats J; Kivelä TT; Pfoehler C; Bhatia S; Huppert P; Van Iersel LBJ; De Vries IJM; Penel N; Vogl T; Cheng T; Fiorentini G; Mouriaux F; Tarhini A; Patel PM; Carvajal R; Joshua AM
    Ann Oncol; 2019 Aug; 30(8):1370-1380. PubMed ID: 31150059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
    Bedikian AY; Legha SS; Mavligit G; Carrasco CH; Khorana S; Plager C; Papadopoulos N; Benjamin RS
    Cancer; 1995 Nov; 76(9):1665-70. PubMed ID: 8635073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
    Luke JJ; Callahan MK; Postow MA; Romano E; Ramaiya N; Bluth M; Giobbie-Hurder A; Lawrence DP; Ibrahim N; Ott PA; Flaherty KT; Sullivan RJ; Harding JJ; D'Angelo S; Dickson M; Schwartz GK; Chapman PB; Wolchok JD; Hodi FS; Carvajal RD
    Cancer; 2013 Oct; 119(20):3687-95. PubMed ID: 23913718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
    Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
    Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
    Klemen ND; Wang M; Rubinstein JC; Olino K; Clune J; Ariyan S; Cha C; Weiss SA; Kluger HM; Sznol M
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32209601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients.
    Pons F; Plana M; Caminal JM; Pera J; Fernandes I; Perez J; Garcia-Del-Muro X; Marcoval J; Penin R; Fabra A; Piulats JM
    Melanoma Res; 2011 Jun; 21(3):217-22. PubMed ID: 21467954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
    Schinzari G; Rossi E; Cassano A; Dadduzio V; Quirino M; Pagliara M; Blasi MA; Barone C
    Melanoma Res; 2017 Dec; 27(6):591-595. PubMed ID: 29076951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
    Khoja L; Atenafu EG; Templeton A; Qye Y; Chappell MA; Saibil S; Hogg D; Butler MO; Joshua AM
    Cancer Med; 2016 Oct; 5(10):2792-2799. PubMed ID: 27683208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lactate Dehydrogenase Prior to Transarterial Hepatic Chemoperfusion Predicts Survival and Time to Progression in Patients with Uveal Melanoma Liver Metastases.
    Ludwig J; Haubold J; Heusner TA; Bauer S; Siveke JT; Richly H; Wetter A; Umutlu L; Theysohn JM
    Rofo; 2021 Jun; 193(6):683-691. PubMed ID: 33348383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors.
    Sander MS; Stukalin I; Vallerand IA; Goutam S; Ewanchuk BW; Meyers DE; Pabani A; Morris DG; Heng DYC; Cheng T
    Cancer Med; 2021 Apr; 10(8):2618-2626. PubMed ID: 33724676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of liver metastases from uveal melanoma.
    Rivoire M; Kodjikian L; Baldo S; Kaemmerlen P; Négrier S; Grange JD
    Ann Surg Oncol; 2005 Jun; 12(6):422-8. PubMed ID: 15886904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of liver metastases from uveal melanoma.
    Kodjikian L; Grange JD; Baldo S; Baillif S; Garweg JG; Rivoire M
    Graefes Arch Clin Exp Ophthalmol; 2005 Oct; 243(10):985-93. PubMed ID: 15891893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
    Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
    Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of pembrolizumab for the treatment of metastatic uveal melanoma.
    Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS
    Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.
    Manola J; Atkins M; Ibrahim J; Kirkwood J
    J Clin Oncol; 2000 Nov; 18(22):3782-93. PubMed ID: 11078491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study.
    Tacar SY; Selcukbiricik F; Yilmaz M; Erturk K; Murat Sarici A; Gulturk I; Ayhan M; Tural D
    Melanoma Res; 2021 Oct; 31(5):449-455. PubMed ID: 34039945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic score for patients with advanced melanoma treated with ipilimumab.
    Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
    Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
    Kuk D; Shoushtari AN; Barker CA; Panageas KS; Munhoz RR; Momtaz P; Ariyan CE; Brady MS; Coit DG; Bogatch K; Callahan MK; Wolchok JD; Carvajal RD; Postow MA
    Oncologist; 2016 Jul; 21(7):848-54. PubMed ID: 27286787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.